

We fund, operate, and scale noncore assets - software, devices, workflows, and data - while you retain faculty, gain equity, and secure perpetual internal access.
Your institution has built working innovations that solve real problems internally but remain locked within your walls. These assets span software tools, medical devices, clinical workflows, data sets, training content, and operational methods. They work. They deliver value. But they lack the packaging, support infrastructure, regulatory pathways, and go-to-market resources needed to become external products.
Unlike for traditional biotech patents waiting for licensees, there are no institutional buyers, and hence no value.
We can help unlock this value.
Limited budget and staffing for productization, documentation, quality systems, and ongoing support. Internal teams are stretched thin managing core mission activities.
Traditional spinouts require faculty to leave their academic roles, creating unacceptable disruption to teaching, research programs, and departmental continuity.
Standard licensing templates assume mature patent estates. Your innovations rely on code, know-how, designs, and data rights that lack clear commercial frameworks.
The faculty member becomes scientific co-founder and advisor under a conflict-of-interest plan with time caps, preserving their academic role and responsibilities.
Transfer code, designs, documentation, data rights, and know-how to the new company. Your institution receives equity in exchange at formation.
You receive an irrevocable license for internal use, covering all improvements, future product updates and extensions - free of any present or future charges.
We provide the seed capital and orchestrate future funding rounds. We hire the product team, handle productization, build quality systems, and manage go-to-market. Zero cash required from you.

Contact us today to discuss how we can help transform your working innovations into valuable revenue-generating products.
info@univaraglobal.com
A structured path to unlock value from working innovations that have not yet become revenue generating products.